Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Shanghai City, China Clinical Trials

A listing of Shanghai City, China clinical trials actively recruiting patients volunteers.

Found (69) clinical trials

Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer

We administered TAC(oxaliplatin,FUDR and MMC) 7 days before liver metastasis resection of colorectal cancer. The study endpoints were progression free survival and overall survival as evaluated by intent-to-treat analysis.

Phase

2.33 miles

Learn More »

A Clinical Trial of a Radiation Sensitizer in Radiochemotherapy for Thoracic Esophageal Squamous Carcinoma

Esophageal cancer is one of the most frequent causes of cancer death in the world. The most common type of esophageal cancer is squamous cell carcinoma (SCC) in China. Although concurrent radiochemotherapy is recommended as the standard treatment for advanced esophageal carcinoma, the local failure still reaches up to 44%-54%. …

Phase

2.33 miles

Learn More »

Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation

This study will recruit 2,446 subjects with stable coronary artery disease in no more than 40 research centers in China. All participants met the inclusion criteria will be 1:1 randomized to 3 months or 12 month of DAPT after implanting Firehawk coronary stent.Clinical follow-up will be carried out at 30 …

Phase

2.33 miles

Learn More »

Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

This study is a phase 4 study, to continually access Xalkori to Chinese patients who were recruited in previous studies of Crizotinib in China, and only collect the safety data.

Phase

2.33 miles

Learn More »

Early Initiation of Low Dose Tirofiban for PPCI in STEMI Patients.

Anti-platelet therapy is a key point of acute myocardial infarction (AMI) treatment. Nowadays, dual anti-platelet therapy based on aspirin and ADP-P2Y12 receptor inhibitor is the preferred treatment before primary percutaneous coronary intervention (PPCI). Restricted by pharmacokinetic and pharmacodynamic characteristics, ADP-P2Y12 receptor inhibitors cannot take effect immediately after oral administration. However, …

Phase

2.33 miles

Learn More »

A Pilot Study in Severe Patients With Takayasu Arteritis.

The Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. Previous studies have revealed that methotrexate, tofacitinib, adalimumab, and tocilizumab were effective in controlling disease activity and preventing disease relapse in some TAK patients, especially the latter two biological agents. However, we believed …

Phase

2.33 miles

Learn More »

Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients

The Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks effective well-accepted intervention strategy. Previous studies have revealed that methoxamine, tofacitinib, adalimumab, and tocilizumab were effective in controlling disease activity and preventing disease relapse in some TAK patients. However, we believed that different patients should be prescribed different …

Phase

2.33 miles

Learn More »

A Randomized Non-inferiority Study of Low-dose and Standard-dose Ticagrelor After Intervention for Acute Coronary Syndrome

This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to prevent major adverse cardiovascular and cerebrovascular events in one years after drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus 100mg Aspirin

Phase

2.33 miles

Learn More »

To Evaluate the Efficacy of Afatinib in Advanced Lung Squamous Cell Carcinoma With EGFR Sensitive Mutation

This is an open-label, sing-arm phase IV clinical study which will recruit about 20 patients in China. The main objective of this study is to evaluate the efficacy of afatinib in LSQC patients with EGFR sensitive mutation, and to explore the clinical factors which might be predictive for the effectiveness …

Phase

3.07 miles

Learn More »

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

The investigators designed a randomized control trial to compare the therapeutic effects of exenatide, metformin and their combination for 3 months on reproductive and metabolic improvements of overweight/obese PCOS patients with impaired glucose regulation. The investigators plan to enroll 183 patients. Overweight and obese PCOS patients with newly diagnosed IGT; …

Phase

3.5 miles

Learn More »